Pharmacogenomics in lung cancer: An analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 12, 2005, Pages 2015-2026

  García Campelo, Rosario ^a   Alonso Curbera, Guillermo ^a   Aparicio, L M Antón ^a   Rosell, Rafael ^b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

BRCA1; Cisplatin; DNA repair; ERCC1; Non small cell lung cancer; Nucleotide excision repair; RRM1; XPD

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; HELICASE; IFOSFAMIDE; MESSENGER RNA; NAVELBINE; OXALIPLATIN; PACLITAXEL; STRESS ACTIVATED PROTEIN KINASE;

CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CYTOTOXICITY; DNA REPAIR; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; GENE EXPRESSION; GENE LOCUS; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; LUNG CANCER; PHARMACOGENOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA TRANSCRIPTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA REPAIR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS;

EID: 27744465511     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.12.2015     Document Type: Review

References (69)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer Statistics, 2005. CA Cancer J. Clin. (2005) 55:10-30.
2. BELANI CP, LANGER C: First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer (2002) 38(4):13-19.
3. SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. (2002) 346:92-98.
4. SCAGLIOTTI G, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J. Clin. Oncol. (2002) 20:4285-4291.
5. MARSHALL A: Laying the foundations for personalized inedicine. Nat. Biotechnol. (1997) 16:954-957.
6. ZAMORANO PL, MAHESH VB, BRANN DW: Quantitative RT-PCR for neuroendocrine studies. A minireview. Neuroendocrinology (1996) 63:397-407
7. GINZINGER D: Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp. Hematol. (2002) 30:503-512.
8. JAQUECT R, HILLYER J, LANDIS WJ: Analysis of connective tissues by laser capture microdissection and reverse transcriptase-polymerase chain reaction. Anal. Biochem. (2005) 337:22-34.
9. FINK L, SEEGER W, ERMERT L et al.: Real-time quantitative RT-PCR after laser-assisted cell picking. Nat. Med. (1998) 4:1329-1333.
10. LOS G, YANG F, SAMINI G et al.: Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry (2002) 47:66-71.
11. PHILLIPS DH: The formation of DNA adducts. The cancer handbook. Nature Publishing Group, London (2002):293-307.
12. WEI Q, CHENG L, HONG WK, SPITZ MR: Reduced DNA repair capacity in lung cancer patients. Cancer Res. (1996) 90:1614-1618.
13. WEI Q, CHENG L, AMOS CI et al.: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiological study. J. Natl. Cancer Inst. (2000) 92:1764-1772
14. BOSKEN CH, WEI Q, AMOS CI, SPITZ MR: An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. (2002) 94:1091-1099.
15. WOOD RD, MITCHELL M, SGOUROS J, LINDAHL T: Human DNA repair genes. Science (2001) 291:1284-1289
16. REED E: Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat. Rev. (1998) 24:331-344.
17. DE BOER J, HOEIJMAKERS JH: Nucleotide excision repair and human syndromes. Carcinogenesis (2000) 21:453-460.
18. HOUTSMULLER AB, RADEMAKERS S, NIGG AL, HOOGSTRATEN D, HOEIJMAKERS JH, VERMEULEN W: Action of DNA repair endonuclease ERCC1/XPF in living cells. Science (1999) 284:958-961.
19. LI Q, YU JJ, MU C et al.: Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in ovarian cancer cells. Anti-Cancer Res. (2000) 20(2A):645-652.
20. SIMON G R, SHARMA S, CANTOR A, SMITH P, BEPLER G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 127:978-983.
21. METZGER R, LEICHMAN CG, DANENBERG KD et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. (1998) 16:309-316.
22. DABHOLKAR M, BOSTICK-BRUTON F, WEBER C et al.: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. (1992) 84:1512-1517.
23. WARNECKE-EBERZ U, METZGER R MIYAZONO F et al.: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res. (2004) 10:3794-3799.
24. SHIROTA Y, STOEHLMACHER J, BRABENDER J et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. (2001) 19:4298-4304.
25. YANG LY, LI L, JIAN H, SHEN Y, PLUNKETT W: Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumour cells defective in mismatch repair but proficient in nucleotide excision repair. Clin. Cancer Res. (2000) 6:773-781.
26. LORD R, BRABENDER J, GANDARA D et al.: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. (2002) 8:2286-2291.
27. ROSELL R, DANENBERG KD, ALBEROLA V et al.: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. (2004) 10:1318-1325.
28. ROSELL R, COBO M, ISLA I et al.: ERCC1 mRNA-based randomized Phase III trial of docetaxel doublets with cisplatin or gerocitabine in stage IV non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2005):Abstr. 7002.
29. HOEIJMAKERS JH, EGLY JM, VERMEULEN W: TFHIIH: a key component in multiple DNA transactions. Curr. Opin. Genet. Dev. (1996) 6:26-33.
30. EVENO E, BOURRE F, QUILLIET X et al.: Different removal of ultraviolet photoproducts in genetically related xeroderma pigmentosum and trichothiodystrophy diseases. Cancer Res. (1995) 5:4325-4332.
31. FURUTA T, UEDA T, AUNE G et al.: Transcription- coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. (2002) 62:4899-4902.
32. VOGEL U, DYBDAHL M, FRENTZ G, NEXO BA: DNA repair capacity: inconsistency between effect of overexpression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat. Res. (2000) 461:197-210.
33. ALOYZ R, XU ZY, BELLO V et al.: Regulation of cisplatin resistance and homologous recombinational repair by TFIIH subunit XPD. Cancer Res. (2002) 62:5457-5462.
34. ARMELINI M, MUOTRI A, MARCHETOO AC et al.: Restoring DNA repair capacity of cells from three distinct diseases by XPD gene-recombinant adenovirus. Cancer Gene Ther. (2005) 4:389-396.
35. ELLEDGE SJ, ZHOU Z, ALLEN JB: Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. Sci. (1992) 17:119-23.
36. JORDAN A, REICHAR P: Ribonucleotide reductase. Annu. Rev. Biochem. (1998) 67:71-98.
37. ZHOU B, LIU X, MO X et al.: The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res. (2003) 63(20):6583-6594.
38. PITTERLE DM, KIM YC, JOLICOEUR EMC, CAO Y, O'BRIANT K, BEPLER G: Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm. Genome (1999) 10:916-922
39. BEPLER G, GAUTAM A, MCINTYRE LM et al.: Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J. Clin. Oncol. (2002) 20:1353-1360.
40. GAUTAM A, LI ZR, BEPLER G: RRM1 induced metastasis suppression through PTEN-regulated pathways. Oncogene (2003) 22:2135-2142.
41. HUANG P, CHUBB S, HERTEL LW, GRINDEY GB, PLUNKETT W: Action of 2′2′-Difluorodeoxycytidine on DNA synthesis. Cancer Res. (1991) 51(22):6110-6117.
42. BAKER CH, BANZON J, BOLLINGER JM: 2′-deoxy-2′2-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem (1991) 34(6):1879-1884.
43. GOAN YG, ZHOU B, HU E, MI S, YEN Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. (1999) 59:4204-4207.
44. DUMONTET C, FABIANOWSKA-MAJEWSDA K, MANTINCIC D et al.: Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. (1999) 106:78-85
45. DAVIDSON J, MA L, FLAGELLA M, GEEGANAGE S, GELBERT LM, SLAPAK CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. (2004) 64(11):3761-3766.
46. BEPLER G, SHARMA S, CANTOR A et al.: RRM1 and PTEN as prognostic parameters for overall survival and disease-free survival in patients with non-small cell lung cancer. J. Clin. Oncol. (2004) 22:1878-1885
47. ROSELL R, SCAGLIOTTI G, DANENBER KD et al.: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 22:3548-3553.
48. ALBEROLA V, CAMPS C, PROVENCIO M et al.: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J. Clin. Oncol. (2003) 21:3207-3213.
49. ROSELL R, FELIP E, TARÓN M et al.: Gene expression as a predictive marker of outcome in stage IIB-IIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. (2004) 10:4215-4219.
50. MIKI Y, SWENSEN J, SHATTUCK-EIDENS D: A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science (1994) 266:66-71.
51. KENNEDY RD, QUINN JE, JOHNSTON PG, HARKIN DP: BRCA1: mechanisms of inactivation and implications for management of patients. Lancet (2002) 360:1007-1014.
52. THOMPSON ME, JENSEN RA, OBERMILLER PS, PAGE DL, HOLT JT: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. (1995) 9(4):444-50.
53. SEERTY LT, KNOWLDEN JM, GEE JM et al.: BRCA1 expression level predict distant metastasis of sporadic breast cancers. Int. J. Cancer (1999) 84:25 8-262.
54. RICE J, OZCELIK H, MAXEINER P, ANDRULIS I, FUTSCHER BW: Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis (2000) 21(9):1761-1765.
55. MARSIT CJ, LIU M, NELSON HH, POSNER M, SUZUKI M, ELSEY KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene (2004) 23:1000-1004.
56. TANIGUCHI T, TISCHKOWITZ M, AMEZIANE N et al.: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumours. Nat. Med. (2003) 9:568-574.
57. THOMPSON LH, SCHILD D: Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. (2001) 477:131-153.
58. GOWEN LC, AVRUTSKAYA AV, LATOUR AM, DOLLER BH, LEADON SA: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science (1998) 281:1009-1012.
59. WANG Y, CORTEZ D, YAZDI P, NEFF N, ELLEDGE SJ, QIN J: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of DNA structures. Genes Dev. (2000) 14:927-939.
60. CORTEZ D, WANG Y, QIN J, ELLEDGE SJ: Requirement of ATM-dependent phosphorylation of BRCA1 in DNA damage response to double-strand breaks. Science (1999) 286:1162-1166.
61. LEE JS, COLLINS KM, BROWN AL, LEE CH, CHUNG JH: hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature (2000) 404:201-204.
62. HSU LC, WHITE RL: BRCA1 is associated with the centrosome during the mitosis. Proc. Natl. Acad. Sci. USA (1998) 95(22):12983-12988.
63. HARKIN DP, BEAN JM, MIKLOS D et al.: Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell (1999) 97:575-586.
64. POTAPOVA O, HAGHIGHI A, BOST F et al.: The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumour cells to cisplatin. J. Biol. Chem. (1997) 272(22):14041-14044.
65. LAFARGE S, SYLVAIN V, FERRARA M, BIGNON YJ: Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene (2001) 20:6597-6606.
66. HUSAIN A, HE G, VENKATRAMAN ES, SPRIGSS DR: BRCA1 upregulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum. Cancer Res. (1998) 58:1120-1123.
67. MULLAN PB, QUINN JE, GILMORE PM et al.: BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene (2001) 20:6123-6131.
68. EGAWA C, MIYOSHI Y, TAKAMURA Y, TAGUCHI T, TAMAKI Y, NOGUCHI S: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int. J. Cancer (2001) 95:255-259.
69. TARÓN M, ROSELL R, FELIP E et al.: BRCA1 mRNA expression levels as an indicator of chemoresistance. Lung Cancer Hum. Mol. Genet. (2004) 20:2443-2449.